Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Nov 20, 2026
TickeronGET DAILY SIGNALS
Profound Medical (PROF) Stock Rises +13% on Q3 Momentum and New Distribution Agreement

Profound Medical (PROF) Stock Rises +13% on Q3 Momentum and New Distribution Agreement

Key Takeaways

  • PROF shares have climbed roughly 13% over the last 30 days, recovering from about $5.69 to near $6.44.
  • The advance was fueled by record preliminary third-quarter revenue, a raised full-year revenue outlook, and a new U.S. distribution agreement with Cook Medical's iMRI division.
  • Over the broader quarter, the stock is essentially flat to slightly lower, underscoring how much of the gain has come in just the past month.
  • Third-quarter 2026 revenue rose 86% year over year, beating analyst estimates as TULSA-PRO system placements accelerated.
  • Profound Medical remains unprofitable, and analysts hold a consensus "Strong Buy" rating with an average price target near $11.
  • For deeper detail on valuation and expectations, explore Profound Medical's Price Targets, Earnings, and Forecast pages.
  • Discover how algorithmic strategies are approaching this market by exploring Trending AI Robots.

Profound Medical (PROF) Business and Market Position

Profound Medical Corp. is a commercial-stage medical device company focused on AI-powered, MRI-guided, incision-free systems for ablating diseased tissue. Its flagship TULSA-PRO platform uses real-time MRI, robotic transurethral ultrasound, and closed-loop temperature control to treat prostate conditions as an alternative to surgery or radiation. The company also offers Sonalleve for certain women's health applications. With an expanding installed base and growing U.S. presence, PROF operates in the image-guided ablation space, where investors watch closely for signs that system placements and procedure volumes can translate into lasting revenue growth.

PROF Stock Performance Over the Past 30 Days Versus the Quarter

In the last 30 days, PROF advanced about 13%, moving from a late-October close near $5.69 to a recent level around $6.44. The move was not linear: shares jumped after an early-October revenue preview, eased mid-month, then picked up again in early November on third-quarter results and the distribution announcement before some profit-taking set in.

Over the full quarter the picture is flatter. From a mid-August close near $6.65, the stock ended modestly lower after dipping into the $5.50–$5.90 range in September and then recovering. The recent 30-day gain has largely restored earlier losses rather than pushing decisively above prior highs.

Catalysts Behind the Recent 30-Day Advance

The first major spark came on October 7 with preliminary third-quarter revenue that topped expectations, lifting shares after hours. The update highlighted record quarterly revenue from stronger TULSA-PRO placements. Momentum built on October 30 when the company announced a U.S. distribution agreement with Cook Medical’s iMRI division, which investors viewed as a step toward faster commercial uptake. Earlier that month, an education partnership with Telix Pharmaceuticals added to the positive backdrop.

Results released on November 5 confirmed an 86% year-over-year revenue increase and raised full-year guidance to $25 million or more. A planned leadership change, with President Richard Fabian becoming CEO in January 2027, gave investors additional developments to assess. Some of the gains have since been trimmed by profit-taking and typical small-cap medical-device volatility. When reviewing peer comparisons, I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Quarterly Context and Commercial Execution

Across the broader quarter, PROF moved in a wide range as investors weighed faster revenue growth against ongoing losses. The period began near $6.80–$7.00, weakened in September amid broader market pressure on small-caps, and then rebounded as commercial progress became clearer.

Management has stressed scaling TULSA-PRO utilization and placements. The Cook Medical partnership is expected to add momentum in the second half of 2027, with a larger effect likely in 2028. Leadership transitions, including the upcoming CEO change, bring an execution element into focus. The net result has been a volatile quarter that closed with most losses recovered and fresh upward momentum heading into year-end.

Key Factors Investors Will Watch Next

Going forward, attention will center on sustained TULSA-PRO placements and procedure volumes to support the raised full-year guidance. Early traction and scaling of the Cook Medical agreement will be monitored closely, given the expected contribution ramp in 2028. The January 2027 CEO transition adds another variable. Broader conditions such as interest rates and funding access for small-cap device companies remain relevant, along with any clinical, reimbursement, or regulatory updates. Analyst consensus currently stands at “Strong Buy” with an average price target near $11.

Exploring AI-Driven Trading Approaches

In my own research, I often look at Tickeron’s AI Trading Bots to see how systematic strategies are positioned around names like PROF. The platform highlights a selection of bots drawn from a much larger set, focusing on those showing strong recent relevance and performance across different timeframes and risk profiles. This can offer a data-driven complement to traditional analysis when evaluating opportunities in the medical-device space.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: PROF

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


PROF's RSI Oscillator recovers from overbought zone

The 10-day RSI Indicator for PROF moved out of overbought territory on November 12, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 36 instances where the indicator moved out of the overbought zone. In 34 of the 36 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PROF as a result. In 83 of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.

The Moving Average Convergence Divergence Histogram (MACD) for PROF turned negative on November 19, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 31 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 74%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PROF declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.

Bullish Trend Analysis

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

PROF moved above its 50-day moving average on October 30, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for PROF crossed bullishly above the 50-day moving average on November 05, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 19 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 74%.

Following a +6.95% 3-day Advance, the price is estimated to grow further. Considering data from situations where PROF advanced for three days, in 198 of 258 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.

PROF may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 100 of 149 cases where PROF Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 67%.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating steady price growth. PROF’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 45 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.289) is normal, around the industry mean (4.142). P/E Ratio (-7.283) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (10.194) is also within normal values, averaging (40.124).

The Tickeron PE Growth Rating for this company is 57 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PROF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Abbott Laboratories (NYSE:ABT), Medtronic plc (NYSE:MDT), Boston Scientific Corp (NYSE:BSX), Edwards Lifesciences Corp (NYSE:EW).

Industry description

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

Market Cap

The average market capitalization across the Medical/Nursing Services Industry is 6.17B. The market cap for tickers in the group ranges from 837 to 190.22B. ABT holds the highest valuation in this group at 190.22B. The lowest valued company is DHAI at 837.

High and low price notable news

The average weekly price growth across all stocks in the Medical/Nursing Services Industry was -11%. For the same Industry, the average monthly price growth was -15%, and the average quarterly price growth was -18%. MXCT experienced the highest price growth at 15%, while CODX experienced the biggest fall at -50%.

Volume

The average weekly volume growth across all stocks in the Medical/Nursing Services Industry was -35%. For the same stocks of the Industry, the average monthly volume growth was -2% and the average quarterly volume growth was -21%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 48
P/E Growth Rating: 50
Price Growth Rating: 64
SMR Rating: 89
Profit Risk Rating: 94
Seasonality Score: 16 (-100 ... +100)
Real Time Patterns 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
Interesting Articles
A.I. Advisor
published General Information

General Information

a developer and manufacturee of therapeutic platforms that combine real-time magnetic resonance imaging with directional and focused ultrasound technology

Industry MedicalNursingServices

Industry
N/A
Address
2400 Skymark Avenue
Phone
+1 647 476-1350
Employees
162
Web
https://www.profoundmedical.com
Interact to see
Advertisement
The ADR gapped lower in premarket trading and was at $335.71 in early regular-session trading, -4.65% from Thursday's close of $352.09. The move extends a global AI and chip unwind: investors are cutting crowded semiconductor bets on stretched valuations, rising sector debt, data-center opposition and Nvidia's leadership turmoil, and Nvidia's strong quarter failed to calm sentiment.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.
Meta Platforms fell from a $596.22 previous close to $583.40, a -2.15% move, with the decline built in premarket trading and held through early Friday action after Thursday's -3.27% drop. The drop was sector-driven, not company-specific: Anthropic slid roughly -6% to -10% premarket on its second trading day, reviving doubts that AI spending will generate returns, and AI-linked megacaps sold off broadly with Nasdaq 100 futures down about -1.5%.
ANT dropped from Thursday's record-debut close of $97.17 to about $88.56 in Friday premarket trading, a -8.86% move ahead of the opening bell, still above its $83 IPO price. The decline came from a broad AI and technology selloff rather than any Anthropic-specific disclosure: Nvidia and AMD traded lower premarket, index futures were sharply down, and renewed doubts over AI spending and valuations drove profit-taking after the +17.07% first-day gain.
IREN dropped -8.33% to $13.21 from Thursday's $14.41 close, with weakness building in premarket and extending through the first hour of regular trading. The decline extends a sector-wide neocloud rout: Anthropic's post-IPO slide and turmoil at Nvidia revived doubts about debt-funded AI data center spending, dragging CoreWeave and Nebius down with it; no IREN-specific news was released.